Core Viewpoint - China Health Group (00673) announced a subscription and rights issue to address financial challenges and capital needs for ongoing operations and future development [1][2] Group 1: Subscription Agreements - The company entered into Subscription Agreements A, B, and C on April 30, 2025, to issue a total of 700 million new shares at a subscription price of HKD 0.1 per share [1] - The subscription price represents a discount of approximately 28.6% compared to the closing price of HKD 0.140 per share on April 30 [1] - The total number of subscription shares represents about 142.4% of the existing shares as of the announcement date and approximately 52.3% of the expanded share capital post-issue [1] Group 2: Rights Issue Details - The company proposes a rights issue based on a ratio of 3 new shares for every 10 shares held at a price of HKD 0.1 per share, aiming to raise between approximately HKD 14.7 million and HKD 15 million [2] - The estimated gross proceeds from the subscription and rights issue are approximately HKD 84.7 million, with net proceeds expected to be around HKD 80.9 million [2] Group 3: Use of Proceeds - The net proceeds from the subscription and rights issue are planned to be used as follows: approximately HKD 65.3 million for settling payables, including HKD 31.2 million for judgment debts, HKD 15.5 million for loans, HKD 3.6 million for overdue employee salaries, HKD 5.1 million for overdue professional fees, and HKD 9.9 million for overdue director remuneration [2] - The remaining balance of approximately HKD 15.6 million will be allocated for the company's working capital [2] Group 4: Resumption of Trading - Following the announcement, the company has applied to resume trading of its shares starting from 9:00 AM on May 23, 2025 [2]
中国卫生集团(00673)拟发行合计7亿股，及按“10供3”基准进行供股